Brief: Schott Pharma Says Expects FY 2026 EBITDA Margin Of Around 27%

SCHOTT Pharma AG & Co KgaA

04/12/2025 17:56

Dec 4 (Reuters) - SCHOTT Pharma AG & Co KgaA 1SXP.DE:

EQS-ADHOC: SCHOTT PHARMA AG & CO. KGAA: OUTLOOK FOR FISCAL YEAR 2026 AND UPDATE OF MID-TERM GUIDANCE

: PRELIMINARY RESULTS FOR FISCAL YEAR 2025 ARE IN LINE WITH MARKET EXPECTATIONS

FOR FY 2026 COMPANY EXPECTS REVENUE GROWTH AT CONSTANT CURRENCIES IN RANGE OF 2-5%

: EXPECTS FY 2026 EBITDA MARGIN OF AROUND 27%

UPDATES 2027-2029 OUTLOOK TO 6-8% REVENUE CAGR

Source text: ID:nEQbNRTmxa

Further company coverage: 1SXP.DE

 ((Reuters.Briefs@thomsonreuters.com;))